drug
pimecrolimus
Marketedupdated 2mo agoby Bausch & Lomb Holdings Inc (Inactive)
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for atopic eczema and eczematoid dermatitis and 10 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying pimecrolimus
- phase3A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
- phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
- —10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
- phase1A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis
- phase1A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
- —Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that